Japanese National Institute of Infectious Diseases Scientists Identify Hemispherx Biopharma’s Drug Technology as the “Most Promising Mucosal Adjuvant for Influenza”

PHILADELPHIA, June 4, 2009 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE Amex:HEB) announced today that a new peer reviewed publication titled “Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses” was published in Therapeutics and Clinical Risk Management 2009:5 125-132. The article summarizes ongoing research in which researchers conclude that Poly I:PolyC12U (Ampligen(r)), an experimental therapeutic, is the “most promising adjuvant candidate for mucosal vaccines.” Poly I:PolyC12U (Ampligen(r)), an experimental therapeutic, was also “extremely important” in these studies, in that it produced cross-protection against variant influenza viruses not seen with the vaccines given alone.